Table 1

 Clinical characteristics of the 226 patients enrolled in the study

CharacteristicValue
Results are expressed as median (interquartile range) unless stated otherwise.
*On a 10 cm VAS.
Age (years)66 (57–74)
Women, No (%)165 (73)
Duration of disease (years)8.6 (4.2–17.9)
Number of months receiving MTX51 (19–97)
Presence of rheumatoid factors (IgM), No (%)156 (69)
Administration of low dose corticosteroids, No (%)107 (47)
Weekly MTX dose (mg)15 (10–17.5)
Folic acid supplementation, No (%)184 (81)
Number of tender joints1.0 (0–5.0)
Number of swollen joints3.0 (1.0–6.0)
Physician’s global assessment of disease activity (10 cm VAS)2.5 (1.2–4.3)
Modified Health Assessment Questionnaire0.375 (0–0.750)
Physician’s assessment of patient’s response to MTX >2 cm (poor response)*, No (%) of patients113 (50)